Skip To Main Content
Richard Smith on Muck Rack

Richard Smith

Clapham, London
As seen in: BBC, The Daily Mirror, The Guardian, The Wall Street Journal, TIME, Washington Post Opinions, New York Daily News, PLOS, BMJ Open, POLITICO and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Healio Special Report: Healthcare Policy

|
By Michael Monostra Verified, Richard Smith
| Citeline Verified
Key takeaways: The ADA estimates that 474,655 Medicaid beneficiaries with diabetes will lose coverage by 2034. As many as 654,000 people with diabetes could lose their Affordable Care Act health plan by 2027. Nearly half a million Americans with diabetes who are currently Medicaid beneficiaries may lose their coverage by 2034 due to policy changes, according to a report from the American Diabetes Association.
Open in Who Shared View Duplicates (2) Issue with article?

CKD prevalence reaches 36 million in US, with increasing ties to diabetes

|
By Lucas Laboy, Richard Smith, Keith Bellovich
| Citeline Verified
Key takeaways: More patients met criteria for chronic kidney disease with the presence of albuminuria vs. eGFR measurements. The prevalence of diabetes-associated CKD increased significantly during the study. About 36 million U.S. adults have chronic kidney disease, with increasing prevalence tied to diabetes, according to study data published in The New England Journal of Medicine.
Open in Who Shared Issue with article?

Remdesivir may offer kidney, CV benefits for transplant recipients with acute COVID-19

|
By Lucas Laboy, Richard Smith
| Citeline Verified
Key takeaways: Early remdesivir treatment reduced risks for graft loss and CV events up to 1 year. Antiviral treatment for transplant recipients should be tailored to a patient’s clinical status and other factors. Kidney transplant recipients with acute COVID-19 had reduced risks for graft loss and CV events when they received early remdesivir, according to study data published in JAMA Network Open.
Open in Who Shared Issue with article?
See all 2,448 licensed articles (2,513 Total)